| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/10/2004 | EP1395253A2 Treatment of anxiety disorders |
| 03/10/2004 | EP1395240A1 Modification of the sustained release profile |
| 03/10/2004 | EP1395133A2 Polymer controlled induced viscosity fiber system and uses thereof |
| 03/10/2004 | EP1395132A1 Dual viscosity fibre system and uses thereof |
| 03/10/2004 | EP1395128A2 Acid controlled viscosity fibre system and uses thereof |
| 03/10/2004 | EP1100499B1 Use of eletriptan for the prevention of migraine recurrence |
| 03/10/2004 | EP0980245B1 Use of misoprostol or/and misoprostol acid for the treatment of erectile dysfunction |
| 03/10/2004 | EP0792147B1 Pharmaceutical composition comprising non-steroidal anti-inflammatory drugs |
| 03/10/2004 | CN1481504A Screening assay for antagonists of human leukocyte receptors |
| 03/10/2004 | CN1481390A Immunomodulatory peptidesderived from heat shock proteins and uses thereof |
| 03/10/2004 | CN1481381A Diphenyl azetidinone derivatives, method for prodn. thereof medicaments contg. these compounds, and their use |
| 03/10/2004 | CN1481373A 1,5-benzothiazepines compounds and its use as antilipemic agent |
| 03/10/2004 | CN1481368A Gyrase imhibitors and uses thereof |
| 03/10/2004 | CN1481367A Imidazole and benzimiddzole caspase inhibitors and uses thereof |
| 03/10/2004 | CN1481360A 蕈毒碱拮抗剂 Muscarinic antagonist |
| 03/10/2004 | CN1481256A Inhalation of nitric oxide |
| 03/10/2004 | CN1481254A Adjuvant compsn comprising immunostimulatory oligonucleotide and tocol |
| 03/10/2004 | CN1481251A Combined method for treating viral infections |
| 03/10/2004 | CN1481249A 治疗hiv的方法 Hiv treatment methods |
| 03/10/2004 | CN1481244A Pharmaceutical formulation contg pyrazolo [4,3-D] pyrinidines, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 03/10/2004 | CN1481243A Pharmaceutical formulation contg. thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 03/10/2004 | CN1481242A Pharmaceutical formulation contg thienopyrimidines and antithrombotics, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| 03/10/2004 | CN1481241A Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 03/10/2004 | CN1481240A Antilipemic agents |
| 03/10/2004 | CN1480218A Medicinal preparation of slowly-released bioactive substance, its prepn. and application |
| 03/10/2004 | CN1480217A Medicinal preparation and its prepn. and application |
| 03/10/2004 | CN1480216A Compound antimicrobial for treating wound of body surface and its preparing method |
| 03/10/2004 | CN1480212A Application of neurotoxin therapy in treatment of urinary system and relative diseases |
| 03/10/2004 | CN1480139A Local medical compsn contg cholinergic medicine or calcium passage retardant |
| 03/10/2004 | CN1480134A Combination of iodine amino acid as well as its preparation method and application |
| 03/09/2004 | US6704749 Integrated hangtag production system |
| 03/09/2004 | US6703486 Peripheral nervous system specific sodium channels |
| 03/09/2004 | US6703485 Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof |
| 03/09/2004 | US6703424 Dispersible compositions containing L-DOPA ethyl ester |
| 03/09/2004 | US6703413 Production of apoptotic films for direct contact with tumors |
| 03/09/2004 | US6703400 Methods for treating multidrug resistance |
| 03/09/2004 | US6703393 Treatment of a variety of central nervous system (cns) disorders in humans, domesticated companion animals and livestock animals. treatment of anxiety, depression, a sleep disorder, attention deficit disorder, or alzheimer's dementia, |
| 03/09/2004 | US6703389 Optically pure reboxetine or its methanesulfonate salt inhibits reuptake of norepinephrine |
| 03/09/2004 | US6703382 Promoting apoptosis by administering compounds such as 2,9-dimethoxy-11,12-dihydrodibenzo(c,g)(1,2)diazocine-5,6-dioxide; anticancer agents |
| 03/09/2004 | US6703381 Administering amphiphilic enkephalin-oligomer conjugate |
| 03/09/2004 | US6703377 Viscosity; biodegradability; fibroblast growth factor |
| 03/09/2004 | US6703371 Preparations for reducing oxygen consumption during physical efforts |
| 03/09/2004 | US6703369 Lipase inhibiting compositions |
| 03/09/2004 | US6703215 Detecting preferential enzyme inhibitor; obtain substrate, incubate with enzyme mixture, expose to enzyme inhibitor, monitor for decrease in enzymatic activity |
| 03/09/2004 | US6703214 Microscopic nematodes in functional high throughput in vivo assays for detection of inhibitors or activators of intestinal lipid uptake |
| 03/09/2004 | US6703050 Methods and compositions for the prevention or treatment of cancer |
| 03/09/2004 | US6702839 Method of controlling body temperature while reducing shivering |
| 03/09/2004 | US6702683 Metering and packaging of controlled release medication |
| 03/09/2004 | CA2322188C The use of fumaric acid derivatives in transplant medicine |
| 03/09/2004 | CA2260992C Eye treatments using synthetic thyroid hormone compositions |
| 03/04/2004 | WO2004018999A2 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 03/04/2004 | WO2004018710A2 Diagnosis of chronic rejection |
| 03/04/2004 | WO2004018678A1 Preventives/remedies for cancer |
| 03/04/2004 | WO2004018648A2 Methods for treating patients and identifying therapeutics |
| 03/04/2004 | WO2004018491A1 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 03/04/2004 | WO2004018043A1 A pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease |
| 03/04/2004 | WO2004018041A1 Use of a ppar-alpha agonist to treat weight gain associated with a ppar-gamma agonist treatment |
| 03/04/2004 | WO2004018010A2 Methods of drug delivery using sulphated chitinous polymers |
| 03/04/2004 | WO2004018000A2 Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents |
| 03/04/2004 | WO2004017993A1 Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension |
| 03/04/2004 | WO2004017984A1 Method for cancer therapy using herbal extracts |
| 03/04/2004 | WO2004017962A2 Tropical formulation comprising at least 5% of metronidazole in white petrolatum and its use in the anal and rectal region |
| 03/04/2004 | WO2004017960A1 Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
| 03/04/2004 | WO2004017954A1 Agent for reducing side effects of diclofenac |
| 03/04/2004 | WO2004017948A2 Use of lck inhibitor for treatment of immunologic diseases |
| 03/04/2004 | WO2004017946A1 Treating alzheimers using delipidated protein particles |
| 03/04/2004 | WO2004017944A1 Liposomal gemcitabine compositions for better drug delivery |
| 03/04/2004 | WO2004017941A2 Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist |
| 03/04/2004 | WO2004017923A2 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix |
| 03/04/2004 | WO2004017917A2 Method for the prevention and/or treatment of atherosclerosis |
| 03/04/2004 | WO2004017916A2 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition |
| 03/04/2004 | WO2004017915A2 Composition for the carrying and delivery of bone growth inducing material and methods for producing and applying the composition |
| 03/04/2004 | WO2004017906A2 Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
| 03/04/2004 | WO2004017896A2 Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist |
| 03/04/2004 | WO2004017894A2 Nutritional supplement for children |
| 03/04/2004 | WO2004017727A1 A method of treatment and prophylaxis |
| 03/04/2004 | WO2004009015A3 Combination therapy for the treatment of obesity |
| 03/04/2004 | WO2004001059A3 Heterocyclic inhibitors of kinases |
| 03/04/2004 | WO2004000229A3 Treatment of human multiple myeloma by curcumin |
| 03/04/2004 | WO2003105901A3 Use of aromatase inhibitors for the treatment of growth failure |
| 03/04/2004 | WO2003097871A8 Marker molecules associated with lung tumors |
| 03/04/2004 | WO2003097091A3 Glucan-based vaccines |
| 03/04/2004 | WO2003083485A3 Protein for use in hypoxia related conditions |
| 03/04/2004 | WO2003082216A9 Neuroprotectant methods, compositions, and screening methods thereof |
| 03/04/2004 | WO2003080104A3 Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases |
| 03/04/2004 | WO2003073107A3 Neuropeptide receptor and uses thereof |
| 03/04/2004 | WO2003072787A3 Method for detection of leptin receptor ligands |
| 03/04/2004 | WO2003068128A3 Massage appliance comprising a storage container and a setting mechanism for setting a characteristic massage value |
| 03/04/2004 | WO2003065871A3 Methods and compositions for treating hematological disorders |
| 03/04/2004 | WO2003055980A3 Il-17 like molecules and uses thereof |
| 03/04/2004 | WO2003055442A3 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
| 03/04/2004 | WO2003054018A3 Anti-tirc7 antibodies in therapy of inflammatory diseases |
| 03/04/2004 | WO2003049527A3 Mitotic kinesin inhibitors |
| 03/04/2004 | WO2003043640A3 Treatment of major depressive disorder using glucocorticoid receptor antagonists |
| 03/04/2004 | WO2003039466A8 Method of treating estrogen responsive breast cancer |
| 03/04/2004 | WO2003033025A3 Cyclodextrin complexes |
| 03/04/2004 | WO2003032904A3 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| 03/04/2004 | WO2003026581A3 Pharmaceutical compositions and methods for treating cancer |
| 03/04/2004 | WO2003019198A3 Methods relating to treatment of atherosclerosis |
| 03/04/2004 | WO2003019196A3 Diagnosis and treatment of atherosclerosis |